Citations

Clear

623 citation(s) found for "Torres, V".

PRRX1-rearranged Fibroblastic Tumors
Torres‐Mora, Jorge , Thangaiah, Judith Jebastin, Oliveira, André M. , Malik, Faizan , Din, Nasir Ud , Hassan, Usman , Maqbool, Hina , Caragea, Mara, Schubart, Christian, Grundtmann, Bo, Melchior, Linea Cecilie , Talman, Maj‐Lis, Cheah, Alison L., Thway, Khin , Fisher, Cyril , Torres-Mora, Jorge, Oliveira, Andre, Dehner, Carina , Michal, Michael , Obeidin, Farres , Lee, Cheng‐Han , Schubart, Christian, Agaimy, Abbas , Gross, John , Antonescu, Cristina R. , Linos, Konstantinos

Mayo Clinic

American Journal of Surgical Pathology | October 2, 2025 | Volume: 50 | Issue: 1 | Pages: 31-40

10.1097/pas.0000000000002472 | PMID 41036703 Get It

With the first series of PRRX1 -rearranged tumors published in 2019, the spectrum of these so-called fibroblastic tumors has been expanded. Since then, several smaller case series have been published; however, our understanding of them continues to be quite limited given their rarity. We herein studied 18 additional cases, the largest series to date. Eighteen tumors present in 9 male, 8 female, and 1 nonbinary patient with a median age of 35 years (range: 11 to 70 y) and involved the neck (5), the chest region (4), thigh (3), back (1), shoulder (1), forehead (1), lower leg (1), axilla (1), and the parapharyngeal region (1). Clinical follow-up (9/18 tumors; 50%; median: 10 mo; range: 4 to 40 mo) showed consistent indolent behavior without local recurrences or distant metastases. On morphology, these tumors were characterized by well-circumscription and distinctive peripheral crescent-shaped vessels. They were composed of uniform spindle and round cells growing in short fascicles within often densely hyalinized collagen lacking significant mitotic activity, necrosis, or cytologic atypia. Immunohistochemically, about half of the tested tumors expressed focal to rarely diffuse S100 with occasional co-expression of SOX10. Interestingly, almost half of the tested cases also showed complete loss of RB expression. All but 1 tumor harbored a PRRX1::NCOA1 fusion, while 1 case harbored a novel PRRX1::EP300 fusion. We herein provide additional data on these exceptionally uncommon tumors, expand their molecular spectrum, and compare them to their close morphologic mimics to aid in accurate diagnosis and avoid confusion with potentially more aggressive neoplasms.
Short-course versus long-course antibiotic treatment for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials
Fite, Amsalu, Farooqi, Mashood , Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Samreen Rizwan Ahmed, Sahra, Syeda , Torres, Antoni, Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, Nihar Yogesh, Cheema, Huzaifa Ahmad , Singh, Harpreet , Ahmad, Sharjeel , Ahmad, Faran , Torres, Antoní

Mayo Clinic

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine | September 25, 2025 | Volume: 9 | Issue: 5 | Pages: 247-254

10.1080/24745332.2025.2552193 Get It

A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions
Manzano, Giovanna S. , Balaban, Denis , Zhang, Yihan , Healy, Brian C. , Chwalisz, Bart K. , Levy, Michael , Venna, Nagagopal, Stern, Barney J. , Pardo, Carlos A. , Rjeily, Nicole Bou , Redenbaugh, Vyanka , Aksamit, Allen J. , Herman, Max Joseph, Rodriguez, Elsa, Snider, Laura, Rains, Hannah G , Montalvo, Mayra , Ramirez, Sergi Martinez, Horta, Lucas, Clardy, Stacey , Cho, Tracey , Samudralwar, Rohini, Torres, Noellie Rivera, Clifford, David B. , Majed, Masoud , Zabeti, Aram , Marcucci, Samuel , Mao‐Draayer, Yang , Doty, John D. , Agyei, Paunel, Bhattacharyya, Shamik , Berger, Joseph R. , Samudralwar, Rohini D , Dunham, S Richard , Levy, Michael , Clardy, Stacey L , Bhattacharyya, Shamik , Manzano, Giovanna Sophia , Balaban, Denis T , Cho, Tracey A , Pardo, Carlos A , Venna, Nagagopal , Barreras, Paula , Flanagan, Eoin P. , Hutto, Spencer K , Herman, Max, Sammak, Sally El , Snider, Laura, Rempe, Torge , Ramirez, Sergi Martinez, Lord, Jennifer, Abdel-Wahed, Lama , Torres, Noellie Rivera, Dunham, Steven , Doty, Jon

Mayo Clinic

Annals of Clinical and Translational Neurology | September 18, 2025 | Volume: 12 | Issue: 12 | Pages: 2589-2599

10.1002/acn3.70200 | PMID 40963302 Get It

ABSTRACT Objective The optimal treatment for neurosarcoidosis myelitis is uncertain. We characterize incident neurosarcoidosis myelitis and assess treatment response by MRI and clinical scales. Methods Incident probable or definite neurosarcoidosis myelitis in adults was retrospectively identified from 13 academic medical centers. Cases were analyzed by initial treatment. The primary outcome was T1 post‐contrast gadolinium enhancement resolution at 6 months post‐treatment. Secondary outcomes were changes in modified Rankin scale (mRS) and Expanded Disability Status Scale (EDSS) from nadir to final follow‐up. Results Two hundred two patients were identified (median diagnosis age: 47 years (IQR 39–55); male: female 1.3:1). Median nadir mRS and EDSS were 2 (IQR 2–3) and 4 (IQR 2.5–6). At initial treatment, 129 (63.9%) received prolonged corticosteroids ≥ 4 weeks (group A 1 ), 36 (17.8%) received corticosteroids < 4 weeks (B 1 ), 21 (10.4%) received corticosteroids plus sarcoidosis‐directed immunosuppressant (E), and 16 (7.9%) received corticosteroids plus non‐sarcoidosis‐directed agents (F). In 167 cases with sufficient imaging, there were no significant differences in contrast enhancement resolution at 6 months (A 1 27/106 (25.5%), B 1 9/28 (32.1%), E 5/19 (26.3%), F 5/14 (35.7%); Fisher's exact p = 0.76). There were no significant differences in changes in mRS or EDSS among treatment groups (Kruskal–Wallis p = 0.69 and 0.63, respectively) after median follow‐up of 46.5 months (IQR 18–91.3). Interpretation Different initial immunosuppression strategies did not correlate with MRI contrast enhancement resolution at 6 months or clinical scales (mRS, EDSS). However, conclusions are limited by retrospective design, imbalanced cohorts, and insensitivity of binary MRI outcomes and available clinical scales for treatment response in neurosarcoidosis.
Response to the Letter to the editor – the ‘self’ in self-management: rethinking mindset and motivation in youth cardiovascular prevention
Chavez, Maria B Mateo, Loor-Torres, Ricardo , Boehmer, Kasey, Burchill, Luke J. , Loor-Torres, Ricardo J , Burchill, Luke J , Chavez, Maria Mateo

Mayo Clinic

European Journal of Cardiovascular Nursing | September 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjcn/zvaf188 | PMID 42495952 Get It

Global consensus statement on the management of pregnancy in inflammatory bowel disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie D. , Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B.

Mayo Clinic

Gut | September 9, 2025 | Volume: 75 | Issue: 2 | Pages: 208-251

10.1136/gutjnl-2025-336402 | PMID 40876906 Get It

Background & aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 Consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Torres, Joana , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla, Long, Millie D. , IBD, Global Consensus Group for Pregnancy and, Maria, Abreu, Ali, Azzam Nahla, Wafaa, Badre, Rupa, Banerjee, Sally, Bell, Susan, Connor, Iris, D, Marc, Ferrante, Emily, Feneberg, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Juliao, Fabián, Leolin, Katsidzira, Alicia, Sambuelli, Christian, Selinger, Astrid, Williams, Jessica, L Thomson, Nicole, A. Capela, Wenli, Chen, Natalie, Hayden, Chun, Lin, Brosbol, Ravnborg Anne, Njeri, Mwaura-Ruhio Treza, Lindsay, Rous, Chaparro, María , Flanagan, Emma , Friedman, Sonia , Julsgaard, Mette , Ng, Siew C , Torres, Joana , Yamamoto-Furusho, Jesus , Barnes, Edward L , Friedman, Sonia , Ng, Siew C. , Robinson, Christopher James , Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Ali, Azzam Nahla, Marc, Ferrante, Emily, Finlayson, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Wei, Shu‐Chen , Zaltman, Cyrla , Wenli, Chen, Lindsay, Rous

Mayo Clinic

Journal of Crohn’s and Colitis | September 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf129 | PMID 40914850 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Evaluating the Total Healthcare Cost of Inappropriately Ordered Thyroid Ultrasounds
Toro-Tobón, David , Thao, Viengneesee , Jacome, Cristian Soto , Larios, Felipe , Guevara, Kerly , Andrango, Luis Vilatuna, Proano, Ana Cristina , Loor-Torres, Ricardo , Zahidy, Misk Al, Cabezas, Esteban , Wu, Yucheng , Ospina, Naykky Singh , Larios, Felipe , Soto Jacome, Cristian, Vilatuna Andrango, Luis, Fan, Jungwei W, Al Zahidy, Misk, Branda, Megan E. , Singh Ospina, Naykky , Brito, Juan P , Toro-Tobon, David , Borah, Bijan J. , Fan, Jungwei , Wu, Yuqi, Brito, Juan P.

Mayo Clinic

Journal of the Endocrine Society | August 30, 2025 | Volume: 9 | Issue: 10 | Pages: No page available

10.1210/jendso/bvaf143 | PMID 40980541 Get It

Abstract Purpose Overuse of thyroid ultrasound (TUS) has contributed to rising thyroid cancer diagnoses and is projected to increase US healthcare costs from $1.5 billion to $3.5 billion by 2030. This study evaluated the healthcare cost of inappropriately ordered TUS in a national multicenter academic system. Methods This is a secondary cost analysis of a retrospective cohort study across 4 Mayo Clinic sites (Rochester, MN; Jacksonville, FL; Scottsdale, AZ; and the Midwest Mayo Clinic Health System). Adult patients (≥18 years) undergoing their first TUS between January 1, 2017, and December 31, 2021, with at least 1 year of follow-up were included. TUS indications were classified as appropriate or inappropriate using a guideline-based natural language processing algorithm. The primary outcome was a comparison of adjusted 1-year all-cause healthcare costs. A secondary analysis calculated the direct procedural costs of the inappropriate TUS cascade. Results Among 6984 patients (mean age 56 [SD 16.4]; 76.2% female; 90.9% White), 546 (7.8%) underwent TUS for inappropriate indications. These patients were younger (mean age 53.0 vs 56.3 years, P &lt; .0001) but otherwise demographically similar. Adjusted total healthcare costs over 90 days and 1 year were comparable: $4842 vs $5794 and $13 748 vs $14 257 for inappropriate vs appropriate TUS, respectively. The inappropriate TUS cascade, including an estimated 56 subsequent biopsies and 22 thyroidectomies, resulted in a minimum of $576 134 in direct procedural costs. Conclusion While adjusted total costs were similar, inappropriate TUS represents potentially avoidable spending and remains a viable target for cost-reduction strategies. Reducing low-value imaging remains a critical target for cost-saving interventions.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L., Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L., Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 28, 2025 | Volume: 62 | Issue: 11-12 | Pages: 1125-1180

10.1111/apt.70290 | PMID 40874657 Get It

ABSTRACT Background & Aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High‐quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data‐driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla C. , Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

American Journal of Gastroenterology | August 27, 2025 | Volume: 121 | Issue: 1 | Pages: 31-79

10.14309/ajg.0000000000003651 | PMID 40862489 Get It

Introduction: Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods: The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results: The topics were divided into 10 categories with 34 GRADE recommendations and 35 Consensus statements. Discussion: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Genetic and Cellular Architecture of Breast Cancer Risk Across Ancestries
Zanti, Maria , Williams, Jacob , Jahagirdar, Om , Turcan, Alistair, Brandenburg, Jean‐Tristan , Li, Jingmei, Miranda, Patricio , Godbole, Devika , Zhang, Xiaomeng , Dorling, Leila , Dennis, Joe, John, Esther M. , Kushi, Lawrence H., Carvajal‐Carmona, Luis G. , Haiman, Christopher A. , Ziv, Elad , Easton, Douglas F. , Chanock, Stephen J., Chatterjee, Nilanjan , Kraft, Peter, Wong, Wendy S W , Zhu, Qianqian , Ahearn, Thomas U., Li, Jingmei , Zhang, Haoyu , John, Esther M , Li, Jingmei , Ziv, Elad , Li, James , Jia, Guochong , Hu, Qiang , Li, Yàn , Ho, Weang-Kee , Dias, Julie‐Alexia , Chen, Wenlong Carl , Boddicker, Nicholas , Wang, Ying , Martin, Alicia R. , Zhang, Yan , Torres-Mejı́a, Gabriela , Kushi, Lawrence H, Weitzel, Jeffrey N. , Neuhausen, Susan L. , Fejerman, Laura , Zheng, Wei , Huo, Dezheng , Chanock, Stephen Jacob , Chatterjee, Nilanjan , García‐Closas, Montserrat , Michailidou, Kyriaki , Zhang, Martin Jinye , Dutta, Diptavo , Ahearn, Thomas U.

Mayo Clinic

No container title available | August 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.20.25334075 | PMID 40909829 Get It

Abstract Background Breast cancer genome-wide association studies (GWAS) have identified more than 200 susceptibility loci, but most studies are dominated by European and East Asian populations. Methods We analyzed breast cancer GWAS summary statistics from African (AFR), East Asian (EAS), European (EUR), and Hispanic/Latina (H/L) samples (159,297 cases and 212,102 controls). We estimated logit-scale SNP-based heritability, polygenicity, and cross-ancestry genetic correlation, partitioned heritability across functional annotations, and integrated GWAS results with the Tabula Sapiens single-cell atlas using scDRS+. Results The logit-scale heritability of breast cancer ranged from ℎ 2 =0.47 (SE = 0.07) in EAS to AFR ℎ 2 =0.61 (SE = 0.10), with no significant differences across ancestries (p=0.63). The estimated number of susceptibility markers in a sparse normal-mixture effects model also varied from 4,446 (SE = 3,100) in EAS to 8,308 (SE = 2,751) in AFR, but differences were not significant across ancestries (p=0.55). Cross-sample genetic correlations varied, with the strongest correlation between EUR and EAS (𝜌 = 0.79, SE = 0.08) and weakest between AFR and H/L (𝜌 = 0.26, SE = 0.24). Regulatory annotations were enriched for breast cancer heritability across samples. Integration with single-cell expression profiles implicated ancestry-shared associations with innate immune, secretory epithelial, and stromal cell types. Conclusion These results indicate substantial cross-ancestry sharing of breast cancer polygenic architecture, highlight a consistent contribution of regulatory variation, and identify convergent cellular contexts that motivate functional follow-up and inform expectations for the transferability and attainable performance of common-variant risk prediction across populations.